Literature DB >> 10688272

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.

M L Dahl1, F Sjöqvist.   

Abstract

A short review of the metabolism of psychoactive drugs and the pharmacogenetic factors regulating the enzymes involved is presented here. The potential clinical usefulness of phenotyping and genotyping individuals, with regard to their drug metabolic capacity, is discussed. Indications for genotyping CYP2D6 and a flow scheme for the combined use of conventional therapeutic drug monitoring (TDM) and pharmacogenetic methods for optimizing dosage-schedules of psychoactive drugs are suggested.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10688272     DOI： 10.1097/00007691-200002000-00024

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Review: therapeutic drug monitoring in pediatrics.

Authors:  Offie Porat Soldin; Steven J Soldin
Journal:  Ther Drug Monit       Date:  2002-02       Impact factor: 3.681

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Therapeutic drug monitoring for tomorrow.

Authors:  Erik Eliasson; Jonatan D Lindh; Rickard E Malmström; Olof Beck; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 4.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.

Authors:  Wim J Tamminga; Johan Wemer; Berend Oosterhuis; Anthonius de Boer; Stan Vranckx; Ben F H Drenth; Rokus A de Zeeuw; Lou F M H de Leij; Jan H G Jonkman
Journal:  Eur J Clin Pharmacol       Date:  2003-03-18       Impact factor: 2.953

Review 6.  Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

Authors:  Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.

Authors:  Guillermo Gervasini; Julio Benítez; Juan Antonio Carrillo
Journal:  Eur J Clin Pharmacol       Date:  2010-06-27       Impact factor: 3.064

8.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

9.  Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy.

Authors:  Anick Bérard; Andrea Gaedigk; Odile Sheehy; Christina Chambers; Mark Roth; Pina Bozzo; Diana Johnson; Kelly Kao; Sharon Lavigne; Lori Wolfe; Dee Quinn; Kristen Dieter; Jin-Ping Zhao
Journal:  Front Pharmacol       Date:  2017-07-17       Impact factor: 5.810
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.